Integra LifeSciences (NASDAQ:IART) Updates Q4 Earnings Guidance

Integra LifeSciences (NASDAQ:IART) issued an update on its fourth quarter earnings guidance on Monday morning. The company provided earnings per share guidance of $0.81-0.89 for the period, compared to the consensus earnings per share estimate of $0.87. The company issued revenue guidance of $441-451 million, compared to the consensus revenue estimate of $448.48 million. Integra LifeSciences also updated its FY 2024 guidance to 2.410-2.490 EPS.

Integra LifeSciences Trading Up 1.3 %

Shares of NASDAQ:IART traded up $0.31 during trading on Tuesday, hitting $24.43. The company had a trading volume of 183,678 shares, compared to its average volume of 1,094,289. The stock has a market cap of $1.90 billion, a price-to-earnings ratio of 83.17, a price-to-earnings-growth ratio of 0.66 and a beta of 1.08. The company has a debt-to-equity ratio of 1.17, a current ratio of 3.39 and a quick ratio of 2.10. The company has a fifty day simple moving average of $18.62 and a two-hundred day simple moving average of $24.46. Integra LifeSciences has a one year low of $16.81 and a one year high of $45.42.

Integra LifeSciences (NASDAQ:IART) last posted its quarterly earnings data on Monday, November 4th. The life sciences company reported $0.41 earnings per share for the quarter, beating analysts’ consensus estimates of $0.39 by $0.02. Integra LifeSciences had a net margin of 1.51% and a return on equity of 14.07%. The business had revenue of $380.80 million for the quarter, compared to analysts’ expectations of $375.81 million. During the same quarter in the previous year, the business posted $0.76 earnings per share. The business’s revenue was down .4% compared to the same quarter last year. As a group, equities analysts forecast that Integra LifeSciences will post 2.45 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts have recently commented on the stock. Morgan Stanley raised their target price on shares of Integra LifeSciences from $24.00 to $27.00 and gave the stock an “underweight” rating in a research report on Monday, July 15th. JMP Securities lowered their price objective on shares of Integra LifeSciences from $40.00 to $35.00 and set a “market outperform” rating for the company in a research note on Tuesday, July 30th. BTIG Research upgraded Integra LifeSciences from a “sell” rating to a “neutral” rating in a research note on Monday, October 7th. Truist Financial cut their price objective on Integra LifeSciences from $26.00 to $21.00 and set a “hold” rating on the stock in a report on Monday, October 14th. Finally, Citigroup reduced their price objective on Integra LifeSciences from $20.00 to $16.00 and set a “sell” rating for the company in a research note on Tuesday, October 1st. Three research analysts have rated the stock with a sell rating, five have given a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $26.50.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.